Sarah Bennett
Family · Annandale, VANPI 1598187700
Payments from drug & device makers
Across 451 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$891
- Biohaven Pharmaceuticals, Inc.$831
- Novo Nordisk$825
- AstraZeneca$627
- Pfizer$619
- plus $5K from 37 others
What the payments were for
- Consulting fees$8008%
- Food & beverage$9,18291%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,082 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 40 | $53,820 |
| FarxigaDapagliflozin Propanediol | 27 | $42,337 |
| ProliaDenosumab | 19 | $32,699 |
| TrulicityDulaglutide | 15 | $30,608 |
| OzempicSemaglutide | 24 | $28,084 |
| JanuviaSitagliptin Phosphate | 15 | $22,498 |
| MyrbetriqMirabegron | 29 | $22,461 |
| VascepaIcosapent Ethyl | 27 | $21,746 |
| MounjaroTirzepatide | 17 | $21,177 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $12,008 |
| SynthroidLevothyroxine Sodium | 36 | $3,070 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $2,764 |
| Atorvastatin Calcium | 215 | $2,318 |
| Duloxetine Hcl | 42 | $1,734 |
| Rosuvastatin Calcium | 137 | $1,717 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $511 | $53,82040 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $891 | $51,78532 claims |
| AstraZenecaFarxiga | $627 | $42,33727 claims |
| AmgenProlia | $435 | $32,69919 claims |
| Novo NordiskOzempic | $825 | $28,08424 claims |
| MerckJanuvia | $20 | $22,49815 claims |
| Astellas Pharma US IncMyrbetriq | $216 | $22,46129 claims |
| GSKBreo Ellipta | $234 | $12,00818 claims |
| AbbVieSynthroid | $1,615 | $3,07036 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $1,05198 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Annandale
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.